Medicus Pharma (MDCX) Retained Earnings (2023 - 2025)

Medicus Pharma (MDCX) posted Retained Earnings of -$64.3 million for Q4 2025, down 1286962260.0% quarter-over-quarter from -$5.0 in Q3 2025.

Medicus Pharma (MDCX) Retained Earnings (2023 - 2025) Analysis & Trends

Medicus Pharma (MDCX) has reported Retained Earnings for 2 consecutive years, with -$64.3 million the latest figure, recorded in Q4 2025.

Retained Earnings for Q4 2025 came in at -$64.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was -$64.3 million (changed N/A YoY), and the FY2025 annual result was -$64.3 million, changed N/A from the prior year.
Retained Earnings was -$64.3 million for Q4 2025 at Medicus Pharma, down from -$5.0 in the prior quarter.
Over five years, Retained Earnings peaked at -$5.0 in Q3 2025 and troughed at -$64.3 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Retained Earnings (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn	29.51 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn	-14.83 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn	-17.87 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn	9.67 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn	66.72 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn	-190.00 Mn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn	78.00 Mn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn	-7.20 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-	-
10	Medicus Pharma	6.91 Mn	-1.69 Mn	-	-64.35 Mn

Download Data